{"nct_id":"NCT04146363","title":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)","status":"COMPLETED","status_verified_date":"2022-11","start_date":"2019-09-24","start_date_type":"ACTUAL","primary_completion_date":"2021-06-21","primary_completion_date_type":"ACTUAL","completion_date":"2022-05-03","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["LLY"]}